Side-by-side · Research reference

MatrixylvsPT-141

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED9/39 cited

BFDA-ApprovedHUMAN-REVIEWED13/41 cited

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

PT-141

MC4R Agonist · FDA-Approved (HSDD)

1.75 mgPer doseVYLEESI (bremelanotide injecti 2019

Pre-sexTimingVYLEESI (bremelanotide injecti 2019

~2.7 hrHalf-lifeVYLEESI (bremelanotide injecti 2019

SQ · Abdomen / thigh · ≥45 min before sex

01Mechanism of Action

Parameter

Matrixyl

PT-141

Primary target

Dermal fibroblastsPaccola 2025

Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023 VYLEESI (bremelanotide injecti 2019

Pathway

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023

Downstream effect

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015

Feedback intact?

—

Origin

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019

Antibody development

—

02Dosage Protocols

Parameter

Matrixyl

PT-141

Formulation concentration

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

—

Application frequency

Twice daily (AM/PM)

Standard cosmeceutical protocol.

—

Duration

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

PRN; reassess if no benefit after 8 doses

In vitro evidence

Fibroblast viability + ECM gene upregulationPaccola 2025

—

Vehicle

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

—

Standard dose

—

1.75 mg SQVYLEESI (bremelanotide injecti 2019

Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.

Frequency

—

PRN, max 8 doses / month

Lower / starter dose

—

1 mg (off-label)

Evidence basis

—

FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019 Clayton 2015

Reconstitution

—

Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.

Timing

—

≥45 min before sexual activity

Half-life

—

~2.7 hrVYLEESI (bremelanotide injecti 2019

04Side Effects & Safety

Parameter

Matrixyl

PT-141

Irritation

Mild erythema, pruritus in sensitive skin (rare)

—

Allergic reaction

Contact dermatitis (uncommon)

—

Systemic absorption

Negligible — topical application only

—

Nausea

—

Common (~40%); often transientVYLEESI (bremelanotide injecti 2019

Flushing

—

Common, transient

Injection site reaction

—

Erythema, mild pain

Headache

—

Common

Hyperpigmentation (focal)

—

Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019

Hypertension (transient)

—

Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019

Pregnancy / OB

—

Contraindicated

Cardiovascular disease

—

Use caution; transient BP rise

Absolute Contraindications

Matrixyl

·Known hypersensitivity to palmitoyl peptides

PT-141

·Uncontrolled hypertension
·Known cardiovascular disease (caution)
·Pregnancy

Relative Contraindications

Matrixyl

·Active dermatitis or open wounds at application site

PT-141

·Pre-existing hyperpigmentation disorders
·MC4R-pathway-dependent psychiatric conditions

05Administration Protocol

Parameter

Matrixyl

PT-141

1. Cleanse

Wash face with gentle cleanser. Pat dry.

Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.

2. Application

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

SQ — abdomen or thigh.

3. Timing

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.

4. Storage

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.

5. Needle

—

Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity

PT-141

— no documented stacks